Skip to main content
European Commission logo print header

Clinical validation of retinal oximetry as a biomarker


Disturbance in oxygenation of the retina of the eye is believed to be involved in many sight-threatening diseases, such as diabetic retinopathy, glaucoma and age-related macular degeneration. Oxymap ehf (SME) has developed an oximeter to measure retinal oxygenation. The oximeter is already used by over 20 research groups and the results of small-scale studies indicate that the oximeter can measure disturbed oxygenation in various common and serious eye diseases.

The Oxymap oximeter is currently only useable for research and the aim of the phase 1 and 2 projects is to validate oximetry for clinical use. This will allow earlier intervention and better monitoring of disease progress, benefiting individual patients. Due to the high prevalence and severity of the diseases, societal and economic gains are also considerable. Moving retinal oximetry from being a research tool only to being a validated clinical biomarker will also create a much larger market for Oxymap.

The phase 1 project will yield a feasibility report, including a business plan. The project will lay the foundation for later uptake of retinal oximetry in clinical practise and the concurrent successful commercialisation.

Call for proposal


See other projects for this call

Sub call




Net EU contribution
€ 50 000,00
Hamrahlio 17
105 Reykjavik

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Ísland Ísland Höfuðborgarsvæði
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00